Recommendations for initial antiretroviral treatment in HIV-infected children. Update 2003;Recomendaciones para el tratamiento antirretroviral de inicio de la infección por el VIH en niños. Actualización 2003

Anales de Pediatria

Volumn 60, Issue 3, 2004, Pages 262-268

  Mellado Pena Ma J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Children; Drugs of choice; Drugs options; Highly active antiretroviral therapy; HIV infection; Initial therapy

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; CHILD; CHILDHOOD MORTALITY; DIARRHEA; DRUG SAFETY; EUPHORIA; FEVER; HALLUCINATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; LIPODYSTROPHY; NAUSEA; NEUTROPENIA; PANCREATITIS; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; REVIEW; SOMNOLENCE; VOMITING;

EID: 2342582665     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058077     Document Type: Review

References (31)

1. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J 2003;22:635-41.
2. Van Rossum AM, Fraaij PL, De Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002;2:93-102.
3. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002;185:1409-16.
4. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61.
5. Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin. Clinical Trial Study Group. J Infect Dis 1997;175:1029-38.
6. Resino S, Bellon J, Gurbindo D, Tomás Ramos J, Antonio León J, José Mellado M, Ángeles Muñoz-Ferná ndez M. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: An observational study. Clin Infect Dis 2003;37:1216-25.
7. Essajee SM, Kim M, González C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children. AIDS 1999;13:2523-32.
8. Sharland M, Di Zub GC, Ramos JT, Blanche S, Gibb D, PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Paediatric European Network for Treatment of AIDS. HIV Med 2002;3:215-26.
9. The Working Group on Antiretroviral Therapy. Guidelines for the use of Antiretroviral Agents in Paediatric HIV Infection. June 25, 2003. (http://www.hivatis.org)
10. Gibb DM, Newberry A, Klein N, De Rossi A, Grosch-Woemer I, Babiker A. Immune repopulation after HAART in previously untreated HIV-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000;355:1333-2.
11. Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, et al. Early multytherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002;2:518-25.
12. rd, et al. Paediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
13. James JS. Protease inhibitors in children: Combination therapy reduced death by two thirds. AIDS Treat News 2001;374:4-5.
14. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors children infected with human immunodeficiency virus type-1. Paediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999;341:1874-81.
15. Peruzzi M, Azzari C, Galli L, Vierucci A, De Martino M. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol 2002;128:365-71.
16. Maddocks S, Dwyer D. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection. Paediatr Drugs 2001;3:681-702.
17. Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs 2002;4:581-607.
18. Chiappini E, Galli L, Azzari C, De Martino M. Interleukin-7 and immunologic failure despite treatment with highly active antiretroviral therapy in children perinatally infected with HIV-1. J Acquir Immune Defic Syndr 2003;33:601-4.
19. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Pediatric AIDS Clinical Trials Group Adherence Subcommittee Paediatric AIDS Clinical Trials Group 377 Study Team. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Paediatrics 2002;109:e61.
20. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H for the PENTA Steering Committee. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003;22:56-62.
21. Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, et al. Paediatric European Network for Treatment of AIDS Executive Committee. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003;22:48-55.
22. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003;32:482-9.
23. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophy syndrome in HIV-infected children. AIDS 2000;14:2123-8.
24. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;5:405-10.
25. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003;22:77-84.
26. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blodd leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002;16:513-8.
27. Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis CR, Pontali E, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis 2003;36:1476-82.
28. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric population: A review. Clin Pharmacokinet 2002;41:1115-33.
29. Burger DM, Van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, et al. Dutch Study Group for Children with HIV-1 Infection. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001;45:701-5.
30. Grupo colaborativo español para la infección VIH pediátrica. CEVIHP. Tratamiento antirretroviral en niños. En: Manual práctico de la infección por VIH en el niño. Barcelona: Prous Science, 2000; p. 437-70.
31. Centers for Disease Control. 1994 revised classificaton system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(rr-12):1-10.